Acelyrin — Technical Presentation (March 2024)
31 slides from Acelyrin's technical presentation, Mar 11, 2024
Slide 1: Izokibep Psoriatic Arthritis Global Phase 2b/3 Topline Results
Izokibep Psoriatic Arthritis Global Phase 2b/3 Topline Results March 11, 2024 Exhibit 99.3
Slide 2: Forward-looking statements
2 This presentation contains statements that are not of historical facts, considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are
Slide 3: PsA Is A Disease With Multiple Manifestations
DactylitisEnthesitis Spondylitis Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations including arthritis, psoriasis, enthesitis (inflammation of dense, non- vascular tissues that connect ligaments and tendons to bone), spondylitis, and dactylitis ~1.6M
Slide 4: Izokibep PsA key takeaways
4 PsA • Izokibep IL-17A inhibition alone achieves rapid improvement in resolution across manifestations of disease • Pre-specified analyses support the potential for differentiation in enthesitis resolution • Higher clinical responses than reported by the IL-17A agents • Results comparable to those
Slide 5: Phase 2b/3 Evaluating Izokibep In PsA
5 Efficacy Endpoints Primary & secondary endpoints, all week 16 • ACR50 (primary) • PASI90 • Resolution of enthesitis (LEI=0) • MDA • ACR20 • PsAID response • HAQ-DI change from baseline Moderate-Active PsA (CASPAR criteria) Screening/ Eligibility > 3 TJC68 and > 3 SJC66 RF and anti-CCP negative at
Slide 6: Similar PK Exposures For PsA Ph 2b/3 Q2W and HS Ph 2b Q2W
6 Similar PK Exposures For PsA Ph 2b/3 Q2W and HS Ph 2b Q2W • All patients received correct aggregate amount of drug and placebo • PK samples collected at every visit demonstrated: - 160mg Q2W PsA PK Exposure Comparable to 160mg Q2W HS PK - 160 mg Q2W PK is much lower than 160 mg QW as expected per
Slide 7: Patient Demographics And Baseline Characteristics
7 Izokibep 160 mg QW n=112 Izokibep 160 mg Q2W n=113 Placebo n=118 51.8 (12.2)49.5 (13.3)52.6 (11.7)Age, mean (SD), years 64 (57.1)67 (59.3)51 (43.2)Male, n (%) 109 (97.3)108 (95.6)110 (93.2)White, n (%) 29.1 (5.9)30.5 (6.6)29.7 (6.0)BMI, mean (SD), kg/m2 103 (92.0)105 (92.9)106 (89.8)PsO, n (%) 7.2
Slide 8: PsA Patient Disposition Through Week 16
8 Screened N=457 Randomized N=351 Placebo n=118 Izokibep 160 mg Q2W n=113 Completed week 16 n=116 Completed week 16 n=106 PsA Patient Disposition Through Week 16 Izokibep 160 mg QW n=112 Completed week 16 n=111 Note: A fourth trial arm evaluating izokibep at 80 mg Q4W (equivalent to ~20 mg Q2W) was
Slide 9: Positive Phase 2b/3 Topline Results
Positive Phase 2b/3 Topline Results 9
Slide 10: ACR50 and ACR70 at Primary Endpoint
5% 23% 25% 0% 10% 20% 30% Week 2 Week 4 Week 12 Week 16 15% 43% 40% 0% 10% 20% 30% 40% 50% Week 2 Week 4 Week 12 Week 16 Improvement in ACR50 through Wk 16 (1) Improvement in ACR70 through Wk 16 (1) * *** *** *** *** *** *** *** ** (1) Week 16 data are from the full analysis set using prespecified n
Slide 11: PASI90 and PASI100 at Primary Endpoint
12% 47% 51% 0% 10% 20% 30% 40% 50% 60% Week 2 Week 4 Week 12 Week 16 12% 58% 64% 0% 10% 20% 30% 40% 50% 60% 70% Week 2 Week 4 Week 12 Week 16 * * * *** *** *** ** ** ** ** *** *** *** Improvement in PASI90 through Wk 16 (1) Improvement in PASI100 through Wk 16 (1) 11 PsA PASI90 and PASI100 at Primar
Slide 12: ACR50 and PASI100 Composite at Primary Endpoint
30% 32% 28% 32% 23% 25% 0% 10% 20% 30% 40% 50% BKZ BIO-naïve BKZ TNF-IR SLK 60mg SLK 120mg 12 ACR50 and PASI100 Composite at Primary Endpoint Robust Composite Responses of Joint and Skin Without The Safety Liabilities of IL-17 A&F Inhibition PsA 2% 31% 34% 0% 10% 20% 30% 40% 50% PBO IZO Q2W IZO QW P
Slide 13: Minimal Disease Activity at Primary Endpoint
14% 42% 41% 0 10 20 30 40 50 Week 16 M D A Re sp on de rs , % PBO IZO 160 mg Q2W IZO 160 mg QW 13 28% 27% 32% 38% 22% 15% 0 10 20 30 40 50 Week 16 M D A Re sp on de rs , % BKZ BIO-Naïve BKZ TNF-IR SLK 60mg SLK 120mg *** *** Significant Achievement of Minimal Disease Activity at Week 16 Minimal Disea
Slide 14: Izokibep Demonstrated Resolution Despite Highest Burden Of Enthesitis
0% 20% 40% 60% 80% 100% LEI 3-6 LEI 5-6 0% 20% 40% 60% 80% 100% LEI 1-2 LEI 1 LEI 2 Range of Top Responses 60% - 88% 35 88a 11 65 74a 56 60a 52a ∆ 14% IzokibepPlacebo n= 12n= 12 8 50a b n= 17 n= 19 n= 18 n= 20 n= 38 n= 29n= 9 n= 17 ∆ 42% Improvement relative to PBO in highest burden of disease not p
Slide 15: Summary Of Safety Through Week 16
15 Izokibep 160 mg QW n=112 Izokibep 160 mg Q2W n=113 Placebo n=118n (%) 81 (72.3)75 (66.4)48 (40.7)Any TEAEs 3 (2.7)2 (1.8)1 (0.8)Serious 8 (7.1)5 (4.4)0TEAEs leading to study discontinuation 5 (4.5)1 (0.9)0General disorders and administration site conditions leading to study discontinuationa 000De
Slide 16: Izokibep PsA key takeaways
16 PsA • Izokibep IL-17A inhibition alone achieves rapid improvement in resolution across manifestations of disease • Pre-specified analyses support the potential for differentiation in enthesitis resolution • Higher clinical responses than reported by the IL-17A agents • Results comparable to those
Slide 17: Izokibep Hidradenitis Suppurativa Phase 2b Long Term 32-Week Data
Izokibep Hidradenitis Suppurativa Phase 2b Long Term 32-Week Data March 11, 2024
Slide 18: Forward-looking statements
18 This presentation contains statements that are not of historical facts, considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but ar
Slide 19: Hidradenitis Suppurativa Is A Devastating Disease Where Exposures Matter
19 ~370,000 HS patients in the U.S.; approximately half of patients are considered to have moderate-to-severe disease Diagnosis rates are estimated to increase 1-3% annually Current therapy options are limited; more complete and faster resolution of disease symptoms remain an unmet need for patients
Slide 20: Izokibep HS key takeaways
20 • Magnitude and depth of responses support hypothesis that the characteristics of izokibep – including small size and highly potent inhibition of IL-17A alone – could deliver differentiated clinical benefit • Resolution of abscesses and nodules (HiSCR100) achieved more rapidly than the other IL-1
Slide 21: HS Phase 2b study design
21 Screening/ Eligibility Part A Exploratory Endpoints Efficacy • HiSCRs 16WBaseline 32W 45W39W 8- w ee k Fo llo w -u p 14 -w ee k Fo llo w -u p / Eo S Izokibep 160 mg QW (n=30) Safety • AEs, SAEs • Safety laboratory, vital signs, physical examination • Presence of ADAs Part B Endpoints Primary • Hi
Slide 22: HS Patient Disposition and Safety Summary
22 Patient Disposition Through Week 32 HS Screened N=243 Randomized N=175 Placebo Q2W n=29 Izokibep 160 mg Q2W n=59 Izokibep 160 mg QW n=57 Completed week 16 n=25 Completed week 16 n=52 Completed week 16 n=43 Completed week 32 n=21 Completed week 32 n=50 Completed week 32 n=34 Placebo QW n=30 Comple
Slide 23: Patient Demographics And Baseline Clinical Characteristics
23 Izokibep 160 mg QW n=57 Izokibep 160 mg Q2W n=59 Placebo n=59 35.3 (11.7)40.3 (10.0)37.2 (11.5)Age, years, mean (SD) 7 (12.3)6 (10.2)9 (15.3)Black, n (%) 39 (68.4)36 (61.0)40 (67.8)Female, n (%) 10.1 (7.0)9.4 (7.1)10.8 (9.4)Disease duration, years, mean (SD) 11.2 (8.8)9.3 (6.7)9.0 (5.2)AN count,
Slide 24: HiSCR75 Response With 160 mg QW Sustained Through Week 32
29% 55% 51% 54% 0% 10% 20% 30% 40% 50% 60% 0 4 8 12 16 20 24 28 32 HiSCR75 responses over time PBO PBO switch to IZO IZO 24 29% 51% 55% 54% 0% 10% 20% 30% 40% 50% 60% PBO (n=24) IZO (n=43) PBO switch to IZO (n=20) IZO (n=35) Week 32 Pa ti en ts (% ) Week 16Week HiSCR75 Response With 160 mg QW Sustai
Slide 25: Week 32 HiSCR Responses Were Robust and Dose Ordered
25 42% 22% 22% 54% 37% 31% 0% 20% 40% 60% HiSCR75 HiSCR90 HiSCR100 160 mg Q2W (n=50) 160 mg QW (n=35) Week 32 HiSCR Responses Were Robust and Dose Ordered HS Source: Results from an open label extension and include all subjects through week 32. Data are from the full analysis set and presented as ob
Slide 26: High Order HiSCR Responses Sustained Through Week 32
51% 29% 54% 55% 35% 17% 37% 45% 35% 13% 31% 35% 0% 10% 20% 30% 40% 50% 60% IZO (n=43) PBO (n=24) IZO (n=35) PBO switch to IZO (n=20) HiSCR 75 HiSCR 90 HiSCR 100 26 Week 16 Week 32 High Order HiSCR Responses Sustained Through Week 32 Rapid Achievement of HiSCR100 in ~1/3 of Patients On 160 mg QW, Inc
Slide 27: Izokibep Reaches Magnitudes Of HiSCR100 Other Agents Have Not Achieved
27 14% 26% 20% 35% 23% 9% 22% 23% 18% 31% 24% 20% 0% 5% 10% 15% 20% 25% 30% 35% 40% IZO WK 32 BE HEARD 1/2 WK 48 SUNRISE WK 52 Week 32 Week 52 IZO Q2W IZO QW BKZ Q2W/Q2W BKZ Q2W/Q4W BKZ Q4W/Q4W SEC Q2W SEC Q4WPBO/IZO Q2W PBO/IZO QW Week 48 PBO/BKZ Q2W PBO/SEC Q2W PBO/SEC Q4W Izokibep Reaches Magnitu
Slide 28: Draining Tunnel Resolution Continued To Improve Through Week 32
-1.8 -2.7 -1.9 -2.6 -3.0 -2.0 -1.0 0.0 0 4 8 12 16 20 24 28 32 PBO PBO switch to IZO IZO -1.8 -1.9 -2.7 -2.6 -3.0 -2.0 -1.0 0.0 PBO (n=19) IZO (n=34) PBO switch to IZO (n=15) 28 Week 16 Week 32 M ea n Ch an ge fr om B as el in e in D ra in in g Tu nn el M ea n Ch an ge fr om B as el in e in D ra in
Slide 29: Reductions In Skin Pain Sustained Through Week 32
29 Week 16 Week 32 -0.9 -2.6 -2.4 -2.6 -3.0 -2.0 -1.0 0.0 PBO (n=12) IZO (n=17) PBO switch to IZO (n=9) M ea n (S D ) C ha ng e fr om B as el in e in S ki n Pa in N RS M ea n (S D ) C ha ng e fr om B as el in e in S ki n Pa in N RS -0.9 -2.4 -2.6 -2.6 -4.0 -3.0 -2.0 -1.0 0.0 0 4 8 12 16 20 24 28 32
Slide 30: DLQI Continued To Improve Through Week 32
30 -2.1 -5.3 -4.1 -4.8 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 0 8 16 24 32 PBO PBO switch to IZO IZO Week 16 Week 32 M ea n (S D ) C ha ng e fr om B as el in e in D LQ I M ea n (S D ) C ha ng e fr om B as el in e in D LQ I -2.1 -4.1 -5.3 -4.8 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 PBO (n=25) IZO (n=43) PBO sw
Slide 31: Izokibep HS key takeaways
31 • Magnitude and depth of responses support hypothesis that the characteristics of izokibep – including small size and highly potent inhibition of IL-17A alone – could deliver differentiated clinical benefit • Resolution of abscesses and nodules (HiSCR100) achieved more rapidly than the other IL-1